Evidence map›Paper›PMID 36757862›Full record

ArticleeLife2023

The forgotten people: Hepatitis B virus (HBV) infection as a priority for the inclusion health agenda.

Emily Martyn, Sarah Eisen, Nicky Longley, Philippa Harris, Julian Surey, James Norman, Michael Brown, Binta Sultan, Tongai G Maponga, Collins Iwuji and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 3 pooled it
34.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 4 countries.

Emily MartynThe Francis Crick Institute, London, United Kingdom.
Sarah EisenHospital for Tropical Diseases, Division of Infection, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Nicky LongleyLondon School of Hygiene & Tropical Medicine, London, United Kingdom.
Philippa HarrisFind & Treat Service, Division of Infection, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Julian SureyFind & Treat Service, Division of Infection, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
James NormanFind & Treat Service, Division of Infection, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Michael BrownLondon School of Hygiene & Tropical Medicine, London, United Kingdom.
Binta SultanFind & Treat Service, Division of Infection, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Tongai G MapongaStellenbosch University, Faculty of Medicine and Health Sciences, Tygerberg, South Africa.
Collins IwujiDepartment of Global Health, Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom.
Stuart FlanaganMortimer Market Centre, Central and North London NHS Foundation Trust, London, United Kingdom.
Indrajit GhoshFind & Treat Service, Division of Infection, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Alistair Story *Find & Treat Service, Division of Infection, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
Philippa C Matthews *The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-4036-4269
University College London Hospitals NHS Foundation Trust · GBBrighton and Sussex Medical School · GBCentral and North West London NHS Foundation Trust · GBStellenbosch University · ZA

Funding

Wellcome Trust 110110Wellcome Trust 110110/Z/15/Z
6 · The paper itself

Abstract

Hepatitis B virus (HBV) infection represents a significant global health threat, accounting for 300 million chronic infections and up to 1 million deaths each year. HBV disproportionately affects people who are under-served by health systems due to social exclusion, and can further amplify inequities through its impact on physical and mental health, relationship with stigma and discrimination, and economic costs. The 'inclusion health' agenda focuses on excluded and vulnerable populations, who often experience barriers to accessing healthcare, and are under-represented by research, resources, interventions, advocacy, and policy. In this article, we assimilate evidence to establish HBV on the inclusion health agenda, and consider how this view can inform provision of better approaches to diagnosis, treatment, and prevention. We suggest approaches to redress the unmet need for HBV interventions among excluded populations as an imperative to progress the global goal for the elimination of viral hepatitis as a public health threat.

Indexed as

Hepatitis BHepatitis B virusGlobal HealthHumansMass ScreeningPublic Healtheliminationepidemiologyglobal healthhealth inequalityhepatitis b virushomelessnessinclusion healthinfectious diseasemicrobiologypublic healthrefugee healthsustainable development goals

Identifiers

PMID36757862
PMCPMC9910830
OpenAlexW4319656103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.